{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:01:52Z","timestamp":1790186512922,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.oret.2022.05.011","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T19:04:48Z","timestamp":1652727888000},"page":"1028-1043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Management of Key Ocular Adverse Events in Patients Implanted with the Port Delivery System with Ranibizumab"],"prefix":"10.1016","volume":"6","author":[{"given":"Carl C.","family":"Awh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Barteselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Makadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay M.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Wieland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Brassard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia F.","family":"Callaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamika","family":"Gune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pam","family":"Heatherton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dante J.","family":"Pieramici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2022.05.011_bib1","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1016\/j.ophtha.2019.09.024","article-title":"Age-related macular degeneration preferred practice pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2022.05.011_bib2","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.oret.2022.05.011_bib3","first-page":"S3","article-title":"Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration","volume":"24","author":"Wykoff","year":"2018","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.oret.2022.05.011_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129361","article-title":"Caregiver burden in patients receiving ranibizumab therapy for neovascular age related macular degeneration","volume":"10","author":"Gohil","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.oret.2022.05.011_bib5","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ajo.2015.06.023","article-title":"Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study","volume":"160","author":"Prenner","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2022.05.011_bib6","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.2147\/OPTH.S92548","article-title":"Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey","volume":"9","author":"Varano","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2022.05.011_bib7","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.ophtha.2019.03.036","article-title":"The Port Delivery System with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 ladder clinical trial","volume":"126","author":"Campochiaro","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2022.05.011_bib8","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.oret.2020.11.004","article-title":"End-of-study results for the Ladder phase 2 trial of the Port Delivery System with ranibizumab for neovascular age-related macular degeneration","volume":"5","author":"Khanani","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2022.05.011_bib9","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/0192623320968079","article-title":"Nonclinical toxicology and biocompatibility program supporting clinical development and registration of the Port Delivery System with ranibizumab for neovascular age-related macular degeneration","volume":"49","author":"Bantseev","year":"2021","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.oret.2022.05.011_bib10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ophtha.2021.09.016","article-title":"Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration","volume":"129","author":"Holekamp","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2022.05.011_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/tvst.9.7.1","article-title":"Virtual reality becomes a reality for ophthalmologic surgical clinical trials","volume":"9","author":"Pieramici","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.oret.2022.05.011_bib12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3928\/23258160-20220408-01","article-title":"Implant insertion procedure of the Port Delivery System with ranibizumab: overview and clinical pearls","volume":"53","author":"Pieramici","year":"2022","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2022.05.011_bib13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3928\/23258160-20220412-01","article-title":"Refill-exchange procedure of the Port Delivery System with ranibizumab: overview and clinical trial experience","volume":"53","author":"Khanani","year":"2022","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2022.05.011_bib14","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3928\/23258160-20220415-03","article-title":"Conjunctiva and Tenon\u2019s capsule handling in the Port Delivery System implant insertion procedure: surgical pearls","volume":"53","author":"Graff","year":"2022","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2022.05.011_bib17","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1097\/IAE.0000000000002614","article-title":"Evaluation of surgical factors affecting vitreous hemorrhage following Port Delivery System with ranibizumab implant insertion in a minipig model","volume":"40","author":"Bantseev","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.oret.2022.05.011_bib18","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2147\/OPTH.S104220","article-title":"Ahmed glaucoma valve implant: surgical technique and complications","volume":"11","author":"Riva","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2022.05.011_bib19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1471-2415-14-107","article-title":"Use of mitomycin C to reduce the incidence of encapsulated cysts following ahmed glaucoma valve implantation in refractory glaucoma patients: a new technique","volume":"14","author":"Zhou","year":"2014","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.oret.2022.05.011_bib20","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.2147\/OPTH.S267010","article-title":"Learning curve and one-year outcome of XEN 45 gel stent implantation in a Swedish population","volume":"14","author":"Busch","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2022.05.011_bib21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/IJG.0000000000001107","article-title":"Glaucoma gel implant learning curve in a teaching tertiary hospital","volume":"28","author":"Marques","year":"2019","journal-title":"J\u00a0Glaucoma"},{"key":"10.1016\/j.oret.2022.05.011_bib22","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1007\/s00417-021-05096-1","article-title":"The learning curve of retinal detachment surgery","volume":"259","author":"Radeck","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2022.05.011_bib23","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.4103\/ijo.IJO_232_21","article-title":"Impact of a structured training program to enhance skills in phacoemulsification surgery","volume":"69","author":"Bhatt","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.oret.2022.05.011_bib24","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/archopht.125.9.1215","article-title":"The resident surgeon phacoemulsification learning curve","volume":"125","author":"Randleman","year":"2007","journal-title":"Arch Ophthalmol"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653022002457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653022002457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:30:47Z","timestamp":1762853447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653022002457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2468653022002457"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2022.05.011","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Key Ocular Adverse Events in Patients Implanted with the Port Delivery System with Ranibizumab","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2022.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}]}}